Meeting
2012 ASCO Annual Meeting
First-in-human study of AMG 900, an oral pan-Aurora kinase inhibitor, in adult patients (pts) with advanced solid tumors.
Authors
Michael Anthony Carducci
The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer, Baltimore, MD
Michael Anthony Carducci , Montaser F. Shaheen , Channing Judith Paller , Julie E. Bauman , Nilofer Saba Azad , Poornima Shubhakar , Rui Tang , Mark Stroh , Gregory R. Friberg , Claire F. Verschraegen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics - Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Cell Cycle and Checkpoints
Clinical Trial Registration Number
NCT00858377
Citation
J Clin Oncol 30, 2012 (suppl; abstr 3009)
DOI
10.1200/jco.2012.30.15_suppl.3009
Abstract #
3009
Poster Bd #
1
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors.
First Author: Melissa Lynne Johnson
Poster
2020 ASCO Virtual Scientific Program
Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.
First Author: Jasmine Huynh
Poster
2020 ASCO Virtual Scientific Program
Pen-866, a miniature drug conjugate of a heat shock protein 90 (HSP90) ligand linked to SN38 for patients with advanced solid malignancies: Phase I and expansion cohort results.
First Author: Gerald Steven Falchook
Poster
2019 ASCO Annual Meeting
A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.
First Author: Nancy Chan